06/17/22 7:30 AMNasdaq : ALT clinical trialAltimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research,RHEA-AIneutral
06/03/22 7:30 AMNasdaq : ALT conferencesAltimmune to Participate at Two Upcoming Investor ConferencesAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022: Jefferies 2022 Global HealthcareRHEA-AIneutral
05/31/22 7:30 AMNasdaq : ALT conferencesclinical trialAltimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliverRHEA-AIneutral
05/20/22 7:30 AMNasdaq : ALT conferencesclinical trialAltimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5 th Global NASH Congress on May 26-27, 2022, in London,RHEA-AIneutral
05/16/22 7:30 AMNasdaq : ALT conferencesAltimmune to Present at Upcoming Investor ConferencesAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global InvestmentRHEA-AIneutral
05/12/22 7:00 AMNasdaq : ALT earningsAltimmune Announces First Quarter 2022 Financial Results and Provides a Corporate UpdateAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporateRHEA-AIneutral
05/05/22 7:30 AMNasdaq : ALT conferencesearningsAltimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update. Altimmune management will hostRHEA-AIneutral
04/01/22 7:00 AMNasdaq : ALT clinical trialAltimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in ObesityAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announcedRHEA-AIneutral
03/15/22 7:01 AMNasdaq : ALT earningsAltimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateAltimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announcedRHEA-AIneutral
03/08/22 7:00 AMNasdaq : ALT conferencesearningsAltimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022. Altimmune management will host a conference callRHEA-AIneutral